Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22469164 | 1.00 | CPA1 (0.37) | CPA1GRIK1GRIK2CYP2C19CNR1 | |
| SCHEMBL17866155 | 0.83 | CPA1 (0.35) | CPA1GRIK1GRIK2CYP2C19ITGB3 | |
| SCHEMBL3609473 | 0.83 | GRIK1 (0.33) | CPA1GRIK1GRIK2 | |
| SCHEMBL3609476 | 0.83 | GRIK1 (0.33) | CPA1GRIK1GRIK2 | |
| SCHEMBL3642955 | 0.83 | GRIK1 (0.33) | CPA1GRIK1GRIK2 | |
| SCHEMBL2792016 | 0.81 | ITGB3 (0.33) | CPA1CNR1ITGB3ITGA2BTSHR | |
| SCHEMBL5823623 | 0.81 | TSHR (0.45) | CPA1CYP2C19CNR1TSHR | |
| SCHEMBL29781257 | 0.79 | PLA2G2C (0.38) | CNR1ABCC4MAPT | |
| SCHEMBL18988133 | 0.79 | PLA2G2C (0.38) | CNR1ABCC4MAPT | |
| SCHEMBL2840047 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4122537-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| EP-3938047-B1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3938047-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3873896-A1 | TRICYCLIC COMPOUNDS AS STING AGONISTS, AND PREPARATION METHODS AND MEDICINAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-09-08 | — | — | EP | disclosed |
| US-11084832-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20160194332-A1 | NOVEL QUINOLINE -SUBSTITUTED COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-3037424-A1 | NOVEL QUINOLINE-SUBSTITUTED COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-06-29 | — | — | EP | disclosed |
| EP-2722332-B1 | QUINOLYLPYRROLOPYRIMIDYL FUSED-RING COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2960241-A1 | METHOD FOR PRODUCING TRICYCLIC COMPOUND, AND TRICYCLIC COMPOUND CAPABLE OF BEING PRODUCED BY SAID PRODUCTION METHOD | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-8889666-B2 | Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2542537-B1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-21 | — | — | EP | disclosed |
| EP-2722332-A1 | QUINOLYLPYRROLOPYRIMIDYL FUSED-RING COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-20140057899-A1 | QUINOLYL PYRROLO PYRIMIDYL CONDENSED-RING COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| EP-2542537-A1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | Phenex Pharmaceuticals AG (DE) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107248-A1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | PHENEX PHARMACEUTICALS AG (DE) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | CPA1 1590/4885GRIK1 3866/4885GRIK2 3654/4885 |
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | CPA1 1188/4885GRIK1 3534/4885GRIK2 4152/4885 |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | CPA1 1590/4885GRIK1 3866/4885GRIK2 3654/4885 |
| US-20140057899-A1 | QUINOLYL PYRROLO PYRIMIDYL CONDENSED-RING COMPOUND AND SALT THEREOF | EGFR, JAK2, ABL1 | CPA1 2086/4885GRIK1 1361/4885GRIK2 1965/4885 |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | CPA1 1590/4885GRIK1 3866/4885GRIK2 3654/4885 |
| US-20160194332-A1 | NOVEL QUINOLINE -SUBSTITUTED COMPOUND | EGFR, ERBB2, ERBB4 | CPA1 2548/4885GRIK1 1386/4885GRIK2 1623/4885 |
| US-11084832-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | CPA1 1590/4885GRIK1 3866/4885GRIK2 3654/4885 |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | STING1, CGAS, MAVS | CPA1 1188/4885GRIK1 3534/4885GRIK2 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.